OCGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Ocugen, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$0.79+0.01 (+0.90%)
Close on Oct 19, 2026
- Market cap
- $266.64M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.8127 (−50.79%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Ocugen, Inc. grew revenue 8.8% to $4.41M over fiscal 2025. Free cash flow was -$61.02M.
Revenue
$4.41M
+8.8% vs. a year earlier
Operating income
-$68.90M
TTM Q2 2026
Free cash flow
-$61.02M
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $266.64M
- P/E ratio
- –
- Price to sales
- 60.42
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -22.89%
Fundamentals
- Revenue
- $4.41M
- Net income
- -$81.81M
- Free cash flow
- -$61.02M
- Book value per share
- -$0.05
- Diluted shares
- 339M
Thirteen years at a glance
Fiscal years 2013 to 2025 and trailing twelve months, USD
Revenue
–
Operating income
-$68.90M
Net income
-$81.81M
EPS, diluted
–
Free cash flow
-$61.02M
Reported periodTrailing twelve months